Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Longitudinal aqueous humor biomarker and retinal imaging study in nAMD and DME under anti-VEGF therapy
2020-003515-10Phase 4Completed
- Sponsor
- Roche
- Start
- Jan 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in exudative macular degeneration and diabetic macular edema (DME), sponsored by Roche. Primary endpoint: Multimodal retinal imaging features over time. Started Jan 2021; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative macular degenerationdiabetic macular edema (DME)
Beyond the preview
Go deeper on 2020-003515-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003515-10.